Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects
At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR)
Itolizumab demonstrated a favorable safety and tolerability profile
Posted In: EQ